




## RFP-PD-2015-001

### Intent to Apply (ITA)

A total of 31 eligible ITA forms were received. A breakdown of eligible ITA forms by disease, intervention and development stage is shown below: \*







*\* One or more ITA forms included multiple diseases, interventions and/or development stages in the scope.*

### Full Proposal


A total of 21 eligible proposals were received. A breakdown of eligible proposals by disease, intervention and development stage is shown below:\*



### Intervention



### Development Stage



\* One or more proposals included multiple diseases, interventions and/or development stages in the scope.

## Award Notification

The following five projects were awarded funding.

Project Title	Collaboration Partners	Disease	Intervention	Development Stage	Total Amount
Live attenuated prophylactic vaccine for leishmaniasis	1. The Ohio State University 2. Institute of Tropical Medicine, Nagasaki University 3. McGill University	Leishmaniasis	Vaccine	Pre-Clinical	¥183,296,715
E209 a tetraoxane based rapidly acting antimalarial – candidate selection	1. Liverpool School of Tropical Medicine 2. University of Liverpool 3. Eisai Co., Ltd.	Malaria	Drug	Pre-Clinical	¥20,775,374
Preclinical development of MVDVax, a new dengue vaccine	1. European Vaccine Initiative 2. Institut Pasteur 3. Institute of Tropical Medicine, Nagasaki University	Dengue	Vaccine	Pre-Clinical	¥61,290,240
Commercial Formulation Development of DSM265	1. Medicines for Malaria Venture 2. Takeda Pharmaceuticals	Malaria	Drug	Clinical Ph2	¥190,534,146
DAR-901 whole cell booster vaccine to prevent TB infection in adolescents ("DAR-PIA")	1. Trustees of Dartmouth College Geisel School of Medicine 2. Muhimbili University of Health and Allied Sciences 3. Tokyo Medical and Dental University	TB	Vaccine	Clinical Ph2	¥142,359,000